Compare GRABW & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRABW | CGEN |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | Singapore | Israel |
| Employees | 11267 | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 143.1M |
| IPO Year | N/A | 2000 |
| Metric | GRABW | CGEN |
|---|---|---|
| Price | $0.33 | $1.55 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 54.7K | ★ 427.1K |
| Earning Date | 02-21-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,686,000,000.00 | $6,903,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $231.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.65 | N/A |
| 52 Week Low | $0.15 | $1.13 |
| 52 Week High | $0.59 | $2.66 |
| Indicator | GRABW | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 49.25 | 50.01 |
| Support Level | $0.29 | $1.43 |
| Resistance Level | $0.34 | $1.59 |
| Average True Range (ATR) | 0.04 | 0.07 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 65.67 | 51.06 |
Founded in 2012, Grab provides ride-sharing services, food and grocery delivery, and financial services (payments, consumer loans, and enterprise offerings) in eight Southeast-Asian countries through its mobile platform. The company partners with merchants and riders, connecting them with consumers while charging commission to both sides. Grab has a leading market share in and derives 89% of its revenue from its core businesses, ride-sharing and food delivery. Singapore, Indonesia, and Malaysia contributed more than 70% of revenue in 2024. Grab's main competitors in Southeast Asia are Line Man and Goto. Its financial services business is still in its nascent stage and provides minimal revenue currently. The company now also generates advertising revenue.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.